Biotechnology - Licensing, Vaccines


Current filters:


Popular Filters

Dutch biotech Mucosis partners with Chinese firm

Dutch biotech Mucosis partners with Chinese firm


Dutch biotech company Mucosis has entered into a long-term collaboration and license agreement with China-based…

BiotechnologyChangchunChief executiveChinaDiseaseHuman respiratory syncytial virusLicensingMimopath technologyNetherlandsVaccines

Valneva deal with Emergent BioSolutions for development of vaccines in the EB66 cell line


European biotechnology company Valneva has signed a new research license agreement and transferred an…

BiotechnologyEB66 cell lineEmergent BioSolutionsLicensingVaccinesValneva

Valneva initiates fourth antibody discovery program for Sanofi Pasteur


European biotechnology company Valneva has initiated a fourth monoclonal antibody discovery program for…

Antibiotics and Infectious diseasesBiotechnologyLicensingResearchSanofiSanofi PasteurVaccinesValneva

Valneva licenses EB66 to IAVI for preventive HIV vaccine


Biotech firm Valneva says that it has licensed the use of its EB66 cell line to the International AIDS…


Agenus and VaxLogic licensing accord on QS-21 Stimulon adjuvant

Agenus and VaxLogic licensing accord on QS-21 Stimulon adjuvant


US biotech firm Agenus has entered into a non-exclusive license agreement with VaxLogic, a subsidiary…

AgenusBiotechnologyLicensingNorth AmericaPharmLogicVaccinesVaxLogic

Immune Design and Medicago link up to develop flu vaccines


Privately-held US biotech firm Immune Design and Medicago (TSX: MDG), a Canadian biopharmaceutical company…

Anti-viralsBiotechnologyImmune DesignLicensingMedicagoVaccines

Licensing deals for Philogen with Pfizer and GlycoVaxyn with Janssen


Privately held Italian biopharma firm Philogen SpA (Siena, Italy) has granted global drugs behemoth Pfizer…

BiotechnologyDekavilGlycoVaxynInflammatory diseasesJanssenJohnson & JohnsonLicensingPfizerPharmaceuticalPhilogenVaccines

Emergent BioSolutions gets exclusive US commercial rights to pandemic flu vaccine candidate


US vaccine maker Emergent BioSolutions (NYSE: EBS) has signed a license agreement with fellow USA-based…

BiotechnologyEmergent BioSolutionsLicensingNorth AmericaVaccinesVaxInnate Corp

Galena Biopharma leaps on deal with Teva for NeuVax in Israel


Shares of US biotech firm Galena Biopharma (Nasdaq: GALE) leapt 13.7% to $2.32 in pre-market trading…

BiotechnologyGalena BioPharmaLicensingnelipepimut-SNeuVaxOncologyRest of the WorldTeva Pharmaceutical IndustriesVaccines

Sanofi inks up to $900 million allergy pact with Selecta Biosciences


US clinical-stage biopharma company Selecta Biosciences revealed this morning that it has entered into…

BiotechnologyImmunologicalsLicensingPharmaceuticalResearchSanofiSelecta BiosciencesVaccines

Silencing investor concerns? Alnylam achieves RNAi milestone


US RNAi therapeutics specialties Alnylam Pharmaceuticals (Nasdaq: ALNY) has received a $3.2 million milestone…

Alnylam PharmaceuticalsAnti-viralsBiotechnologyFinancialGlaxoSmithKlineLicensingProductionVaccines

Vivalis signs another EB66 out-licensing deal for MAb production


French biotech firm Vivalis (NYSE Euronext: VLS) has signed a joint collaboration and commercial license…


Agenus expands deal with GlaxoSmithKline; Nuron in-licenses vaccines


US biotech firm Agenus (Nasdaq: AGEN) says it has amended the QS-21 license and manufacturing agreement…

AgenusAkshaya BioBiotechnologyGlaxoSmithKlineLicensingNuron BiotechPharmaceuticalVaccines

Sanofi Pasteur and CureVac collaborate on a $33.1 million project on vaccines for infectious diseases


Germany’s CureVac says it has signed several agreements with Sanofi Pasteur, the vaccines division…

Antibiotics and Infectious diseasesBiotechnologyCureVacLicensingPharmaceuticalResearchSanofiSanofi PasteurVaccines

Transgene to seek partner for HCV vaccine TG4040 on strong Ph II results


French biotech firm Transgene (Euronext Paris: FR0005175080) has revealed interim data showing a substantial…


Gilead collaborates with GlobeImmune to develop vaccine for chronic hepatitis B infection


Gilead Sciences (Nasdaq: GILD) has entered into an exclusive worldwide license and collaboration agreement…

Anti-viralsBiotechnologyGilead SciencesGlobeImmuneLicensingResearchVaccines

Back to top